GTXI GTx, Inc.

3.37
+0.00  (0%)
Previous Close 3.37
Open 3.36
Price To book 2.70
Market Cap 54.06M
Shares 16,041,000
Volume 17,752
Short Ratio 4.16
Av. Daily Volume 22,220

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17844779
  2. 8-K - Current report 17841065
  3. 8-K - Current report 17832915
  4. 8-K - Current report 17807153
  5. DEF 14A - Other definitive proxy statements 17730836

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2, 2009.
Toremifene
Reduce fractures in men with prostate cancer
Phase 2 prelim data from Stage 1 portion of trial due 2Q 2017.
Enobosarm
Breast cancer - advanced AR+ TNBC
Phase 2 initiated January 2016. Data to be presented at International Continence Society Annual Meeting, September 13, 2017.
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2 initial data released December, 8 2016. Top-line data due 3Q 2017.
Enobosarm
Breast cancer - metastatic or locally advanced, ER+/AR+ breast cancer

Latest News

  1. GTx reports 1Q loss
  2. GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results
  3. GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting
  4. GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics
  5. GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results
  6. GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
  7. Is GTx, Inc. (GTXI) A Good Stock To Buy?
  8. GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
  9. GTx Declares 1-For-10 Reverse Stock Split (GTXI)
  10. GTx, Inc. Announces 1-for-10 Reverse Stock Split
  11. GTx, Inc. :GTXI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  12. Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer
  13. GTx Announces Webcast of Corporate Presentation at the 28th Annual Piper Jaffray Healthcare Conference
  14. Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone
  15. GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer
  16. GTx Announces Webcast of Corporate Presentation at the Stifel 2016 Healthcare Conference
  17. GTx Provides Corporate Update and Reports Third Quarter 2016 Financial Results
  18. Insider Invests in GTx